List view / Grid view

Prof. Klaus Dugi

 

Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.

news

FDA approves linagliptin tablets for the treatment of type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today…

3 May 2011 | By OgilvyHealthPR

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…